ClinicalTrials.gg
RecruitingNCT07229495Updated Oct 13, 2026

Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery

A Phase 4 interventional study of Tegileridine and morphine in Scoliosis; Adolescence, Pain After Surgery and Analgesia, Patient-controlled, sponsored by Peking Union Medical College Hospital. Recruiting at 6 sites in China. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Peking Union Medical College Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Scoliosis with a site in China — 22 open to participants now, 26 under way, none of them phase 3. Scoliosis · China.

Planned enrollment
11th of 37
171 · median 100
Started
2026
with 4 others
Phase 4
3 of 55
1 open now
Primary completion
2027-10
later than 20 of 25 live
Registered
48th of 55
by date
Lead sponsor
3 of 55
Peking Union Medical College Hospital

Among the 55 studies in Scoliosis with a site in China, this one is the 11th largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2026, is one of 3 in phase 4, reaches primary completion later than 20 of the 25 other live ones, and was the 48th registered.

Scoliosis

660 studies on the registry are indexed under Scoliosis; 185 are open to participants now.

Browse Scoliosis studies →

Open to participants now

22 of the 55 studies in Scoliosis with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Scoliosis studies recruiting now, 23 (20%) set no upper age limit and 88 (75%) stop at 75 or younger; 98 take children under 18; 14 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Scoliosis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to see if a new pain medicine called Tegileridine is at least as effective as morphine (the standard treatment) for pain relief after spinal surgery in teenagers with scoliosis. This type of study is called a "non-inferiority" trial. The study will also carefully compare the safety of both medicines.

The main questions it aims to answer are:

Is Tegileridine no worse than morphine at controlling pain in the first 24 hours after surgery? How do the side effects (like sleepiness or nausea) of Tegileridine compare to those of morphine? Researchers will compare two different doses of Tegileridine against morphine. Neither the participants nor the doctors assessing them will know which medicine is being given.

Participants in this study will:

Receive one of the three pain medicine options through a pump (called a PCA pump) that they can control themselves after surgery.

Use the pump for up to 48 hours. Regularly rate their pain levels using a simple number scale. Have their health closely monitored by the study team during this time.

Read the detailed description

This is a prospective, multicentre, randomized, double-blind, controlled, non-inferiority clinical trial designed to evaluate the efficacy and safety of Tegileridine for postoperative analgesia in adolescent patients undergoing spinal fusion surgery for scoliosis.

Postoperative pain management is crucial for recovery, with opioids like morphine being the standard of care. However, morphine is associated with significant side effects, including respiratory depression, nausea, and vomiting. Tegileridine is a novel, highly selective μ-opioid receptor agonist that is hypothesized to provide potent analgesia with an improved safety profile, particularly regarding respiratory depression.

A total of 171 adolescent patients (aged 10 to \<18 years) scheduled for surgery will be enrolled. Participants will be randomly assigned in a 1:1:1 ratio to one of three treatment groups:

Group T1: Tegileridine 20 μg/kg loading dose, followed by patient-controlled analgesia (PCA) at a dose of 1 μg/kg per bolus.

Group T2: Tegileridine 20 μg/kg loading dose, followed by PCA at a dose of 2 μg/kg per bolus.

Group M (Active Comparator): Morphine 60 μg/kg loading dose, followed by PCA at a dose of 20 μg/kg per bolus.

The study medication will be prepared by an unblinded nurse not involved in subsequent patient care or assessment. Upon arrival in the post-anesthesia care unit (PACU) after surgery, the assigned loading dose of the study drug will be administered, immediately followed by the initiation of the PCA pump, which will be maintained for 48 hours. To maintain blinding, the study drugs are diluted in normal saline to appear identical. Patients, attending anesthesiologists, and outcome assessors will all be blinded to the treatment assignment.

The primary objective is to demonstrate the non-inferiority of Tegileridine to morphine in terms of analgesic efficacy. The primary efficacy endpoint is the area under the curve (AUC) of resting pain intensity scores, measured on an 11-point Numerical Rating Scale (NRS), over the first 24 hours after initiating PCA. A predefined non-inferiority margin of 12 will be used for the comparison. Statistical testing will follow a hierarchical procedure, first comparing the T2 group to the morphine group, and if non-inferiority is established, proceeding to compare the T1 group to morphine.

Secondary objectives include comparing the groups on various efficacy measures, such as pain AUC at other time points, rescue analgesic consumption, and patient satisfaction. Safety objectives focus on the incidence and severity of adverse events, with continuous monitoring for postoperative hypoxemia (SpO₂ \< 90%), assessment of sedation levels using the modified Pasero Opioid-induced Sedation Scale (m-POSS), and recording of other common opioid-related side effects like postoperative nausea and vomiting (PONV).

The primary analysis will be conducted on the Full Analysis Set (FAS) and Per-Protocol Set (PPS). Sensitivity analyses and a pre-specified subgroup analysis by gender are also planned.

03

Conditions studied

  • Scoliosis; Adolescence
  • Pain After Surgery
  • Analgesia, Patient-controlled

Keywords

  • Tegileridine
  • Postoperative Pain
  • Adolescent
  • Patient-Controlled Analgesia
  • Scoliosis
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 10 years to less than 18 years.
  • Scheduled to undergo posterior spinal fusion (PSF) surgery for adolescent idiopathic scoliosis under general anesthesia.
  • (ASA) physical status classification I to III.
  • The participant and their parent or legal guardian voluntarily provide written prior to any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Baseline room-air oxygen saturation (SpO2) \< 90% at rest, acute or severe bronchial asthma.
  • History of severe cardiovascular or cerebrovascular disease, such as myocardial infarction, unstable angina, second-degree or higher atrioventricular block, Class III or higher heart failure, or stroke.
  • Known or suspected gastrointestinal obstruction, including paralytic ileus.
  • Known to opioids or any component of the study drug formulation.
  • Severe cognitive impairment or uncontrolled psychiatric disorders (e.g., active schizophrenia) that preclude the patient's ability to comprehend the NRS or independently operate the patient-controlled analgesia (PCA) pump.
  • Diagnosis of neuromuscular scoliosis or presence of any other chronic pain condition that may interfere with postoperative pain assessment.
  • Chronic use of opioid analgesics, or use of any long-acting analgesics within 48 hours prior to surgery (short-acting non-opioid analgesics are permitted but must be discontinued at least 12 hours preoperatively).
  • Planned postoperative admission to the intensive care unit (ICU).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
171 participants (estimated)

Study arms

  • Experimental
    Tegileridine 20 μg/kg Loading Dose + 1 μg/kg PCA

    Participants in this arm will receive an initial intravenous loading dose of 20 μg/kg Tegileridine upon transfer to the post-anesthesia care unit (PACU), immediately followed by postoperative patient-controlled analgesia (PCA). The PCA solution is prepared by diluting Tegileridine in normal saline to a total volume of 200 ml. The PCA pump is programmed to deliver a bolus dose of 1 μg/kg Tegileridine per activation, with a 10-minute lockout interval and no background infusion. PCA therapy will be maintained for at least 48 hours, barring any adverse events requiring discontinuation.

    Drug: Tegileridine

  • Experimental
    Tegileridine 20 μg/kg Loading Dose + 2 μg/kg PCA

    Participants in this arm will receive an initial intravenous loading dose of 20 μg/kg Tegileridine upon transfer to the post-anesthesia care unit (PACU), immediately followed by postoperative patient-controlled analgesia (PCA). The PCA solution is prepared by diluting Tegileridine in normal saline to a total volume of 200 ml. The PCA pump is programmed to deliver a bolus dose of 2 μg/kg Tegileridine per activation, with a 10-minute lockout interval and no background infusion. PCA therapy will be maintained for at least 48 hours, barring any adverse events requiring discontinuation.

    Drug: Tegileridine

  • Active comparator
    Morphine 60 μg/kg Loading Dose + 20 μg/kg PCA

    Participants in this arm will receive an initial intravenous loading dose of 60 μg/kg morphine upon transfer to the post-anesthesia care unit (PACU), immediately followed by postoperative patient-controlled analgesia (PCA). The PCA solution is prepared by diluting morphine in normal saline to a total volume of 200 ml. The PCA pump is programmed to deliver a bolus dose of 20 μg/kg morphine per activation, with a 10-minute lockout interval and no background infusion. PCA therapy will be maintained for at least 48 hours, barring any adverse events requiring discontinuation.

    Drug: morphine

Interventions

  • Tegileridine is a novel μ-opioid receptor-biased agonist. In this study, it is administered as an initial intravenous loading dose immediately followed by patient-controlled analgesia (PCA) for postoperative pain management. The PCA solution is prepared by diluting the Tegileridine injection in normal saline.

  • Morphine is a standard opioid analgesic used as the active comparator in this study. It is administered as an initial intravenous loading dose immediately followed by patient-controlled analgesia (PCA) for postoperative pain management. The PCA solution is prepared by diluting Morphine injection in normal saline.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of Resting Pain Scores on the 11-point Numerical Rating Scale (NRS) Over the First 24 Hours Postoperative

    The analgesic efficacy will be assessed by calculating the Area Under the Curve (AUC) of the resting pain intensity scores over the first 24 hours after initiating Patient-Controlled Analgesia (PCA). Pain Intensity Measurement: Pain intensity is assessed by the participant using an 11-point Numerical Rating Scale (NRS), where 0 represents "no pain" and 10 represents "the worst pain imaginable." Resting state is defined as being in a stationary position without active movement. Assessment Time Points: NRS scores are recorded at predefined time points: 5 minutes, 10 minutes, 15 minutes, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours after the end of the loading dose infusion. AUC Calculation: The AUC for the NRS scores versus time is calculated using the trapezoidal rule, which sums the areas of trapezoids formed between consecutive time points. A lower AUC indicates better and more sustained pain control over the 24-hour period.

    Time frame: From the end of the loading dose infusion up to 24 hours.

Secondary outcomes

  1. Area Under the Curve (AUC) of Resting Pain Scores on the Numerical Rating Scale (NRS) Over Multiple Time Intervals

    The AUC of resting pain intensity scores (measured on an 11-point NRS, where 0 represents "no pain" and 10 represents "the worst pain imaginable") will be calculated using the trapezoidal rule. The AUC will be calculated for the following cumulative time intervals after the end of the loading dose infusion: 0-6 hours, 0-12 hours, and 0-48 hours. A lower AUC indicates better and more sustained pain control over the specified period.

    Time frame: The AUC will be calculated for the cumulative intervals from the end of the loading dose infusion up to 6 hours, 12 hours, and 48 hours.

  2. Area Under the Curve (AUC) of Activity-Induced Pain Scores on the Numerical Rating Scale (NRS) over Multiple Intervals

    The AUC of pain intensity scores during activity (or coughing) measured on an 11-point NRS will be calculated over the intervals of 0-6 hours, 0-12 hours, 0-24 hours, and 0-48 hours after the end of the loading dose infusion. The AUC is calculated using the trapezoidal rule.

    Time frame: Assessed at 6, 12, 24, and 48 hours after the end of the loading dose infusion.

  3. Resting and Activity-Induced Pain Scores on the Numerical Rating Scale (NRS) at Multiple Time Points

    Pain intensity will be assessed using the 11-point NRS (0=no pain, 10=worst pain imaginable) at rest and during activity (or coughing) at the following time points after the end of the loading dose infusion: 5 minutes, 10 minutes, 15 minutes, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 30 hours, 36 hours, 42 hours, and 48 hours.

    Time frame: Assessed at 16 predefined time points from 5 minutes to 48 hours after the end of the loading dose infusion.

  4. Proportion of Participants Requiring Rescue Analgesia

    The percentage of participants who receive rescue analgesia during the PCA treatment period. Rescue analgesia is defined as the administration of additional analgesic medication (e.g., acetaminophen, NSAIDs, or other opioids) when the participant's pain is not adequately controlled (NRS score ≥4) despite receiving the study drug.

    Time frame: From the end of the loading dose infusion up to 48 hours.

  5. Time to First Use of Rescue Analgesia

    The time elapsed from the end of the loading dose infusion to the first administration of any rescue analgesic medication.

    Time frame: From the end of the loading dose infusion up to 48 hours (time to event is measured).

  6. Total Number of Rescue Analgesic Administrations Per Participant

    The total count of rescue analgesic medication administrations required for each participant during the PCA treatment period, when pain was not controlled (NRS ≥4) by the study drug.

    Time frame: From the end of the loading dose infusion up to 48 hours.

  7. Cumulative Dose of Rescue Analgesic Medication

    The total cumulative dose of all rescue analgesic medications used by each participant during the PCA treatment period. Doses of different opioids will be converted to morphine milligram equivalents (MME) for summation.

    Time frame: From the end of the loading dose infusion up to 48 hours.

  8. Proportion of Participants with Pain NRS Score ≤ 3 at Each Assessment Time Point

    The percentage of participants who achieve a pain intensity score of 3 or less (indicating mild pain) on the 11-point NRS at the following time points after the end of the loading dose infusion: 5 minutes, 10 minutes, 15 minutes, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 30 hours, 36 hours, 42 hours, and 48 hours.

    Time frame: Assessed at 16 predefined time points from 5 minutes to 48 hours after the end of the loading dose infusion.

  9. Total Number of PCA Pump Attempts and Successful Deliveries

    The total number of demands (attempts) made by the participant on the PCA pump and the total number of successful drug deliveries (effective deliveries) recorded by the pump during the treatment period.

    Time frame: From the end of the loading dose infusion up to 48 hours.

  10. Postoperative Length of Hospital Stay

    The duration of hospitalization after the surgical procedure, measured from the day of surgery until the day of discharge.

    Time frame: From the day of surgery to the day of hospital discharge, an average of 10 days.

  11. Satisfaction with Pain Treatment

    Participants' satisfaction with pain management is assessed using an 11-point numerical scale (0=extremely dissatisfied, 10=extremely satisfied) within 30 minutes after the cessation of PCA therapy.

    Time frame: At 30 minutes after stopping PCA (typically around 48 hours post-surgery).

  12. Incidence of Postoperative Hypoxemia

    The proportion of participants experiencing postoperative hypoxemia, defined as a percutaneous oxygen saturation (SpO2) reading below 90%, as monitored by pulse oximetry during the PCA treatment period.

    Time frame: From the end of the loading dose infusion up to 48 hours.

  13. Incidence and Severity of Postoperative Nausea and Vomiting (PONV)

    The occurrence and severity of PONV assessed by healthcare personnel using a Visual Analog Scale (VAS) for nausea/vomiting (0=no nausea/vomiting, 10=worst imaginable nausea/vomiting) at specified time points. Severity is categorized as mild (VAS\<4cm), moderate (VAS 4-7cm), or severe (VAS\>7cm).

    Time frame: Assessed at 5 minutes, 10 minutes, 30 minutes, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours after the end of the loading dose infusion.

  14. Level of Sedation as Assessed by the Modified Pasero Opioid-Induced Sedation Scale (m-POSS)

    The level of sedation is assessed by healthcare personnel using the m-POSS, which includes scores from S (sleep, easily aroused) to 4 (somnolent, minimal or no response to stimulus). Higher scores indicate deeper sedation.

    Time frame: Assessed at 5 minutes, 10 minutes, 30 minutes, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours after the end of the loading dose infusion.

  15. Incidence of Other Adverse Events

    The occurrence of other predefined adverse events during the treatment period, including abdominal pain, abdominal distension (time to first flatus and defecation), fever, dizziness, headache, sinus bradycardia, somnolence, and pruritus.

    Time frame: From the end of the loading dose infusion up to 48 hours.

07

Study locations

1 of 6 sites recruiting
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
    Not yet recruiting
    • Mingzhu Cui, Doctor · ContactCuimingzhu78@163.com · +86 18639006993
    • Mingzhu Cui, Doctor · Principal investigator
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Not yet recruiting
    • Xiaoping Zhu, Doctor · Contact13907915506@163.com · + 86 13907915506
    • Xiaoping Zhu, Doctor · Principal investigator
  • Beijing Chao-yang Hospital, Capital Medical University
    Beijing, 100020, China
    Not yet recruiting
    • Changwei Wei, Doctor · Contactchangwei.wei@ccmu.edu.cn · +86 13810678936
    • Changwei Wei, Doctor · Principal investigator
  • Peking Union Medical College Hospital
    Beijing, 100730, China
    Recruiting
    • Juelun Wu, Doctor · Contactpumchwujuelun@163.com · +86 18707486338
    • Ling Lan, Doctor · Principal investigator
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, 200092, China
    Not yet recruiting
  • Shanghai Children's Medical Centre, School of Medicine, Shanghai Jiao Tong University
    Shanghai, 200127, China
    Not yet recruiting
    • Hualin Chen, Doctor · Contact18930329981@163.com · +86 18930329981
    • Jijian Zheng, Doctor · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data (IPD), alongside the study protocol, statistical analysis plan, and analytic code, will be available via a controlled-access process. Access will be granted to qualified researchers with methodologically sound proposals from 6 to 36 months following primary publication. Requesters must contact the corresponding author and sign a formal Data Access Agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Beginning 6 months and ending 3 years after the publication of results

Access criteria: Access to deidentified Individual Participant Data (IPD) will be granted to qualified academic and clinical researchers. To qualify, researchers must submit a methodologically sound research proposal (e.g., for IPD meta-analysis) alongside a detailed statistical analysis plan. Requests will be reviewed by the Principal Investigator and the trial steering committee. Proposals will be evaluated based on scientific merit, methodological rigor, and ethical appropriateness. As the mechanism for data sharing, approved requesters must sign a formal Data Access Agreement (DAA). The DAA strictly limits data use to the approved analytical protocol, completely prohibits any attempts to re-identify participants, and legally binds the requesters to protect adolescent privacy. Requests should be directed to the corresponding author via email. The data will be accessible from 6 to 36 months following the publication of the primary trial results.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2027, 18 months after the start.

Of 19 phase 4 interventional studies under Scoliosis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 37. This study's planned 18 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Jul 2026 → Apr 2026, primary completion Jun 2027 → Oct 2027 and completion Sep 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Nov 17, 2025
StartActual
Apr 8, 2026was Jul 2026
Primary completionEst.
Oct 30, 2027was Jun 2027
CompletionEst.
Dec 30, 2027was Sep 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
6 sites changed recruiting status (5 now not yet recruiting, 1 now recruiting)
Show 6 sites
  • Henan Provincial People's Hospital · Zhengzhou, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Nanchang University · Nanchang, Chinano status→Not yet recruiting
  • Beijing Chao-yang Hospital, Capital Medical University · Beijing, Chinano status→Not yet recruiting
  • Peking Union Medical College Hospital · Beijing, Chinano status→Recruiting
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine · Shanghai, Chinano status→Not yet recruiting
  • Shanghai Children's Medical Centre, School of Medicine, Shanghai Jiao Tong University · Shanghai, Chinano status→Not yet recruiting
Oct 13, 2026
Start date
Jul 1, 2026→Apr 8, 2026 (actual)
Oct 13, 2026
Primary completion
Jun 30, 2027→Oct 30, 2027
Oct 13, 2026
Study completion
Sep 30, 2027→Dec 30, 2027
Oct 13, 2026
Eligibility
1 inclusion criterion edited; 3 exclusion criteria edited, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedScheduled to undergo posterior spinal fusion (PSF) surgery for adolescent idiopathic scoliosis under general anesthesia.
Exclusion criteria
  • EditedHistory of difficult airway, severe respiratory depressionBaseline room-air oxygen saturation (SpO₂SpO2) < 90%) at rest, acute or severe bronchial asthma.
  • ChangedBefore History of psychiatric disorders (e.g., schizophrenia, depression) or cognitive impairment.Now Severe cognitive impairment or uncontrolled psychiatric disorders (e.g., active schizophrenia) that preclude the patient's ability to comprehend the NRS or independently operate the patient-controlled analgesia (PCA) pump.
  • EditedChronic use of opioid analgesics, or use of any analgesic medicationlong-acting analgesics within 48 hours prior to surgery (short-acting non-opioid analgesics are permitted but must be discontinued at least 12 hours preoperatively).
  • RemovedAny other condition deemed by the investigator to be inappropriate for participation in the study.
Oct 13, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameArea Under the Curve (AUC) of Resting Pain Scores on the 11-point Numerical Rating Scale (NRS) Over the First 24 Hours PostoperativeFrom the initiation of Patient-Controlled Analgesia (PCA) up to 24 hours post-initiation. → From the end of the loading dose infusion up to 24 hours.
  • DescriptionArea Under the Curve (AUC) of Resting Pain Scores on the 11-point Numerical Rating Scale (NRS) Over the First 24 Hours Postoperative: how it is measured was reworded
Oct 13, 2026
Secondary outcomes
13 time frame changed, 5 description edited
What changed in the outcomes
  • Time frameArea Under the Curve (AUC) of Resting Pain Scores on the Numerical Rating Scale (NRS) Over Multiple Time IntervalsThe AUC will be calculated for the cumulative intervals from PCA initiation up to 6 hours, 12 hours, and 48 hours post-initiation. → The AUC will be calculated for the cumulative intervals from the end of the loading dose infusion up to 6 hours, 12 hours, and 48 hours.
  • Time frameArea Under the Curve (AUC) of Activity-Induced Pain Scores on the Numerical Rating Scale (NRS) over Multiple IntervalsAssessed at 6, 12, 24, and 48 hours after PCA initiation. → Assessed at 6, 12, 24, and 48 hours after the end of the loading dose infusion.
  • Time frameResting and Activity-Induced Pain Scores on the Numerical Rating Scale (NRS) at Multiple Time PointsAssessed at 16 predefined time points from 5 minutes to 48 hours after PCA initiation. → Assessed at 16 predefined time points from 5 minutes to 48 hours after the end of the loading dose infusion.
  • Time frameProportion of Participants Requiring Rescue AnalgesiaFrom PCA initiation up to 48 hours post-initiation. → From the end of the loading dose infusion up to 48 hours.
  • Time frameTime to First Use of Rescue AnalgesiaFrom PCA initiation up to 48 hours post-initiation (time to event is measured). → From the end of the loading dose infusion up to 48 hours (time to event is measured).
  • Time frameTotal Number of Rescue Analgesic Administrations Per ParticipantFrom PCA initiation up to 48 hours post-initiation. → From the end of the loading dose infusion up to 48 hours.
  • Time frameCumulative Dose of Rescue Analgesic MedicationFrom PCA initiation up to 48 hours post-initiation. → From the end of the loading dose infusion up to 48 hours.
  • Time frameProportion of Participants with Pain NRS Score ≤ 3 at Each Assessment Time PointAssessed at 16 predefined time points from 5 minutes to 48 hours after PCA initiation. → Assessed at 16 predefined time points from 5 minutes to 48 hours after the end of the loading dose infusion.
  • Time frameTotal Number of PCA Pump Attempts and Successful DeliveriesFrom PCA initiation up to 48 hours post-initiation. → From the end of the loading dose infusion up to 48 hours.
  • Time frameIncidence of Postoperative HypoxemiaFrom PCA initiation up to 48 hours post-initiation. → From the end of the loading dose infusion up to 48 hours.
  • Time frameIncidence and Severity of Postoperative Nausea and Vomiting (PONV)Assessed at 5 minutes, 10 minutes, 30 minutes, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours after PCA initiation. → Assessed at 5 minutes, 10 minutes, 30 minutes, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours after the end of the loading dose infusion.
  • Time frameLevel of Sedation as Assessed by the Modified Pasero Opioid-Induced Sedation Scale (m-POSS)Assessed at 5 minutes, 10 minutes, 30 minutes, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours after PCA initiation. → Assessed at 5 minutes, 10 minutes, 30 minutes, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours after the end of the loading dose infusion.
  • Time frameIncidence of Other Adverse EventsFrom PCA initiation up to 48 hours post-initiation. → From the end of the loading dose infusion up to 48 hours.
  • DescriptionArea Under the Curve (AUC) of Activity-Induced Pain Scores on the Numerical Rating Scale (NRS) over Multiple Intervals: how it is measured was reworded
  • DescriptionArea Under the Curve (AUC) of Resting Pain Scores on the Numerical Rating Scale (NRS) Over Multiple Time Intervals: how it is measured was reworded
  • DescriptionProportion of Participants with Pain NRS Score ≤ 3 at Each Assessment Time Point: how it is measured was reworded
  • DescriptionResting and Activity-Induced Pain Scores on the Numerical Rating Scale (NRS) at Multiple Time Points: how it is measured was reworded
  • DescriptionTime to First Use of Rescue Analgesia: how it is measured was reworded
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    6 sites changed recruiting status (5 now not yet recruiting, 1 now recruiting)
    Show 6 sites
    • Henan Provincial People's Hospital · Zhengzhou, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Nanchang University · Nanchang, Chinano status→Not yet recruiting
    • Beijing Chao-yang Hospital, Capital Medical University · Beijing, Chinano status→Not yet recruiting
    • Peking Union Medical College Hospital · Beijing, Chinano status→Recruiting
    • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine · Shanghai, Chinano status→Not yet recruiting
    • Shanghai Children's Medical Centre, School of Medicine, Shanghai Jiao Tong University · Shanghai, Chinano status→Not yet recruiting
    Start date Jul 1, 2026→Apr 8, 2026 (now actual)
    Primary completion Jun 30, 2027→Oct 30, 2027
    Study completion Sep 30, 2027→Dec 30, 2027
    Eligibility 1 inclusion criterion edited; 3 exclusion criteria edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedScheduled to undergo posterior spinal fusion (PSF) surgery for adolescent idiopathic scoliosis under general anesthesia.
    Exclusion criteria
    • EditedHistory of difficult airway, severe respiratory depressionBaseline room-air oxygen saturation (SpO₂SpO2) < 90%) at rest, acute or severe bronchial asthma.
    • ChangedBefore History of psychiatric disorders (e.g., schizophrenia, depression) or cognitive impairment.Now Severe cognitive impairment or uncontrolled psychiatric disorders (e.g., active schizophrenia) that preclude the patient's ability to comprehend the NRS or independently operate the patient-controlled analgesia (PCA) pump.
    • EditedChronic use of opioid analgesics, or use of any analgesic medicationlong-acting analgesics within 48 hours prior to surgery (short-acting non-opioid analgesics are permitted but must be discontinued at least 12 hours preoperatively).
    • RemovedAny other condition deemed by the investigator to be inappropriate for participation in the study.
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameArea Under the Curve (AUC) of Resting Pain Scores on the 11-point Numerical Rating Scale (NRS) Over the First 24 Hours PostoperativeFrom the initiation of Patient-Controlled Analgesia (PCA) up to 24 hours post-initiation. → From the end of the loading dose infusion up to 24 hours.
    • DescriptionArea Under the Curve (AUC) of Resting Pain Scores on the 11-point Numerical Rating Scale (NRS) Over the First 24 Hours Postoperative: how it is measured was reworded
    Secondary outcomes 13 time frame changed, 5 description edited
    What changed in the outcomes
    • Time frameArea Under the Curve (AUC) of Resting Pain Scores on the Numerical Rating Scale (NRS) Over Multiple Time IntervalsThe AUC will be calculated for the cumulative intervals from PCA initiation up to 6 hours, 12 hours, and 48 hours post-initiation. → The AUC will be calculated for the cumulative intervals from the end of the loading dose infusion up to 6 hours, 12 hours, and 48 hours.
    • Time frameArea Under the Curve (AUC) of Activity-Induced Pain Scores on the Numerical Rating Scale (NRS) over Multiple IntervalsAssessed at 6, 12, 24, and 48 hours after PCA initiation. → Assessed at 6, 12, 24, and 48 hours after the end of the loading dose infusion.
    • Time frameResting and Activity-Induced Pain Scores on the Numerical Rating Scale (NRS) at Multiple Time PointsAssessed at 16 predefined time points from 5 minutes to 48 hours after PCA initiation. → Assessed at 16 predefined time points from 5 minutes to 48 hours after the end of the loading dose infusion.
    • Time frameProportion of Participants Requiring Rescue AnalgesiaFrom PCA initiation up to 48 hours post-initiation. → From the end of the loading dose infusion up to 48 hours.
    • Time frameTime to First Use of Rescue AnalgesiaFrom PCA initiation up to 48 hours post-initiation (time to event is measured). → From the end of the loading dose infusion up to 48 hours (time to event is measured).
    • Time frameTotal Number of Rescue Analgesic Administrations Per ParticipantFrom PCA initiation up to 48 hours post-initiation. → From the end of the loading dose infusion up to 48 hours.
    • Time frameCumulative Dose of Rescue Analgesic MedicationFrom PCA initiation up to 48 hours post-initiation. → From the end of the loading dose infusion up to 48 hours.
    • Time frameProportion of Participants with Pain NRS Score ≤ 3 at Each Assessment Time PointAssessed at 16 predefined time points from 5 minutes to 48 hours after PCA initiation. → Assessed at 16 predefined time points from 5 minutes to 48 hours after the end of the loading dose infusion.
    • Time frameTotal Number of PCA Pump Attempts and Successful DeliveriesFrom PCA initiation up to 48 hours post-initiation. → From the end of the loading dose infusion up to 48 hours.
    • Time frameIncidence of Postoperative HypoxemiaFrom PCA initiation up to 48 hours post-initiation. → From the end of the loading dose infusion up to 48 hours.
    • Time frameIncidence and Severity of Postoperative Nausea and Vomiting (PONV)Assessed at 5 minutes, 10 minutes, 30 minutes, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours after PCA initiation. → Assessed at 5 minutes, 10 minutes, 30 minutes, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours after the end of the loading dose infusion.
    • Time frameLevel of Sedation as Assessed by the Modified Pasero Opioid-Induced Sedation Scale (m-POSS)Assessed at 5 minutes, 10 minutes, 30 minutes, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours after PCA initiation. → Assessed at 5 minutes, 10 minutes, 30 minutes, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours after the end of the loading dose infusion.
    • Time frameIncidence of Other Adverse EventsFrom PCA initiation up to 48 hours post-initiation. → From the end of the loading dose infusion up to 48 hours.
    • DescriptionArea Under the Curve (AUC) of Activity-Induced Pain Scores on the Numerical Rating Scale (NRS) over Multiple Intervals: how it is measured was reworded
    • DescriptionArea Under the Curve (AUC) of Resting Pain Scores on the Numerical Rating Scale (NRS) Over Multiple Time Intervals: how it is measured was reworded
    • DescriptionProportion of Participants with Pain NRS Score ≤ 3 at Each Assessment Time Point: how it is measured was reworded
    • DescriptionResting and Activity-Induced Pain Scores on the Numerical Rating Scale (NRS) at Multiple Time Points: how it is measured was reworded
    • DescriptionTime to First Use of Rescue Analgesia: how it is measured was reworded
    + 4 other changes: identifiers, verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07229495
Responsible party
Lan Ling (Principal Investigator, Peking Union Medical College Hospital) — Principal investigator
First posted
Nov 17, 2025
Start date
Apr 8, 2026
Primary completion
Oct 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Juelun Wu, Doctor
Contact
pumchwujuelun@163.com
+86 18707486338
Ling Lan, Doctor
Contact
+86 18612672275
Ling Lan, Doctor
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegileridine

Start the discussion